Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Cancer

Our Cancer theme within the Women's & Reproductive Health department covers the following research groups: HPV research (developing therapeutics to eradicate HPV infections in women), Nanoparticles in Cancer (focussing on the use of nanoparticles in cancer for therapy, imaging or drug delivery), and Ovarian Cancer (exploring the molecular mechanisms that drive Ovarian Cancer cell growth and examining which targeted therapies can be utilised to improve treatment).

© Shutterstock

The Cancer theme is dedicated to advancing research across a broad spectrum of oncology topics, with a particular focus on cervical and ovarian cancer, innovative treatments targeting metabolism, nanoparticle-based therapies, and the application of artificial intelligence in gynaecologic oncology.



Topics in this theme

HPV Research
HPV Research
Our research focuses on the use of nanoparticles in cancer for therapy, imaging or drug delivery.
Nanoparticles in Cancer
NDWRH Clinical Research Group
NDWRH Clinical Research Group
Ovarian cancer is one of the most lethal gynaecological malignancies predominantly because of late presentation and chemotherapy resistance. Recent advances in single cell RNA sequencing and DNA sequencing have made it possible to obtain unprecedented insights into tumour biology. Our lab has developed sequencing strategies and analysis algorithms to accelerate the mechanistic understanding of ovarian cancer initiation, progression and chemotherapy resistance. The use of these technologies and our access to patients recruited in clinical research studies provide exciting opportunities for addressing key questions in ovarian cancer such as a) understanding the cell of origin of ovarian cancer, b) characterising the tumour initiating cells in minimal residual disease and c) understanding T cell immune responses against ovarian cancer initiation and progression.
Ovarian Cancer